{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:21:35Z","timestamp":1740165695869,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"DOI":"10.1007\/s13691-024-00704-3","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T04:15:27Z","timestamp":1722485727000},"page":"427-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synchronous gastric and ovarian cancer successfully treated with FOLFOX therapy: a case report and review of the literature"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8509-0428","authenticated-orcid":false,"given":"Makiko","family":"So","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Shimoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Iemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Suizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichiro","family":"Iwami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahito","family":"Hoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"704_CR1","first-page":"1358","volume":"16","author":"S Warren","year":"1932","unstructured":"Warren S, Gates O (1932) Multiple primary malignant tumor: a survey of the literature and a statistical study. Am J Cancer 16:1358\u20131414","journal-title":"Am J Cancer"},{"key":"704_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/1097-0142(196103\/04)14:2<221::AID-CNCR2820140202>3.0.CO;2-6","volume":"14","author":"CG Moertel","year":"1961","unstructured":"Moertel CG, Dockerty MB, Baggenstoss AH (1961) Multiple primary malignant neoplasmas. Cancer 14:221\u2013230","journal-title":"Cancer"},{"issue":"2","key":"704_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000172","volume":"2","author":"A Vogt","year":"2017","unstructured":"Vogt A, Schmid S, Heinimann K et al (2017) Multiple primary tumours: challenges and approaches, a review. ESMO Open 2(2):e000172","journal-title":"ESMO Open"},{"issue":"16","key":"704_CR4","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.3748\/wjg.v12.i16.2588","volume":"12","author":"JH Lee","year":"2006","unstructured":"Lee JH, Bae S, Ryu KW et al (2006) Gastric cancer patients at high-risk of having synchronous cancer. World J Gastroenterol 12(16):2588\u20132592","journal-title":"World J Gastroenterol"},{"issue":"5","key":"704_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10552-017-0855-5","volume":"28","author":"LE Kelemen","year":"2017","unstructured":"Kelemen LE, Rambau PF, Koziak JM et al (2017) Synchronous endometrial and ovarian carcinomas: predictors of risk and association with survival and tumor expression profiles. Cancer Causes Control 28(5):447\u2013457","journal-title":"Cancer Causes Control"},{"issue":"3","key":"704_CR6","first-page":"280","volume":"19","author":"A Fishman","year":"1998","unstructured":"Fishman A, Aviram R, Beyth Y et al (1998) A second primary malignancy in a cohort of patients with epithelial ovarian cancer\u2014characteristics of diagnosis. Eur J Gynaecol Oncol 19(3):280\u2013283","journal-title":"Eur J Gynaecol Oncol"},{"issue":"17","key":"704_CR7","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1016\/S0959-8049(01)00282-9","volume":"37","author":"K Bergfeldt","year":"2001","unstructured":"Bergfeldt K, Nilsson B, Einhorn S et al (2001) Breast cancer risk in women with a primary ovarian cancer\u2014a case-control study. Eur J Cancer 37(17):2229\u20132234","journal-title":"Eur J Cancer"},{"issue":"2","key":"704_CR8","first-page":"237","volume":"30","author":"T Bozanovi\u0107","year":"2009","unstructured":"Bozanovi\u0107 T, Ljubi\u0107 A, Momocilov P et al (2009) Synchronous primary tumors: appendiceal and ovarian cancer\u2014case report. Eur J Gynaecol Oncol 30(2):237\u2013238","journal-title":"Eur J Gynaecol Oncol"},{"issue":"6","key":"704_CR9","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.21873\/invivo.11699","volume":"33","author":"A Marinello","year":"2019","unstructured":"Marinello A, Ghisoni E, Righi L et al (2019) Women with synchronous or metachronous lung and ovarian cancer: a multi-institutional report. In Vivo 33(6):2021\u20132026","journal-title":"In Vivo"},{"issue":"3","key":"704_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijgo.2014.04.003","volume":"126","author":"OG Olaru","year":"2014","unstructured":"Olaru OG (2014) Synchronous primary serous ovarian cancer and renal cell carcinoma. Int J Gynaecol Obstet 126(3):282","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"704_CR11","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/IGC.0b013e3181b33cce","volume":"19","author":"YRP de Waal","year":"2009","unstructured":"de Waal YRP, Thomas CM, Oei AL et al (2009) Secondary ovarian malignancies: frequency, origin, and characteristics. Int J Gynecol Cancer 19(7):1160\u20131165","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"704_CR12","first-page":"193","volume":"81","author":"H Kajiyama","year":"2019","unstructured":"Kajiyama H, Suzuki S, Utsumi F et al (2019) Epidemiological overview of metastatic ovarian carcinoma: long-term experience of TOTSG database. Nagoya J Med Sci 81(2):193\u2013198","journal-title":"Nagoya J Med Sci"},{"issue":"1","key":"704_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2003.12.039","volume":"93","author":"RG Moore","year":"2004","unstructured":"Moore RG, Chung M, Granai CO et al (2004) Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol 93(1):87\u201391","journal-title":"Gynecol Oncol"},{"issue":"3","key":"704_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.5009\/gnl.2009.3.3.211","volume":"3","author":"HJ Jung","year":"2009","unstructured":"Jung HJ, Lee HY, Kim BW et al (2009) Gastric metastasis from ovarian adenocarcinoma presenting as a submucosal tumor without ulceration. Gut Liver 3(3):211\u2013214","journal-title":"Gut Liver"},{"key":"704_CR15","first-page":"201","volume":"11","author":"S Yang","year":"2018","unstructured":"Yang S (2018) Gastric metastasis of ovarian serous cystadenocarcinoma. Int Med Case Rep J 11:201\u2013204","journal-title":"Int Med Case Rep J"},{"issue":"3","key":"704_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4143\/crt.2012.44.3.173","volume":"44","author":"JY Kim","year":"2012","unstructured":"Kim JY, Jang WY, Heo MH et al (2012) Metachronous double primary cancer after diagnosis of gastric cancer. Cancer Res Treat 44(3):173\u2013178","journal-title":"Cancer Res Treat"},{"key":"704_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/02841869109091804","volume":"30","author":"G Lundegardh","year":"1991","unstructured":"Lundegardh G, Hansson LE, Nyren O et al (1991) The risk of gastrointestinal and other primary malignant diseases following gastric cancer. Acta Oncol 30:1\u20136","journal-title":"Acta Oncol"},{"key":"704_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1349-7006.1991.tb02700.x","volume":"82","author":"T Hiyama","year":"1991","unstructured":"Hiyama T, Hanai A, Fujimoto I (1991) Second primary cancer after diagnosis of stomach cancer in Osaka, Japan. Jpn J Cancer Res 82:762\u2013770","journal-title":"Jpn J Cancer Res"},{"issue":"5","key":"704_CR19","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.21873\/invivo.12987","volume":"36","author":"T Aoyama","year":"2022","unstructured":"Aoyama T, Ju M, Komori K et al (2022) The clinical impact of synchronous and metachronous other primary cancer in gastric cancer patients who receive curative treatment. In Vivo 36(5):2514\u20132520","journal-title":"In Vivo"},{"issue":"11","key":"704_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","volume":"25","author":"S Chen","year":"2007","unstructured":"Chen S, Parmigiani G (2007) Meta\u2013analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25(11):1329\u20131333","journal-title":"J Clin Oncol"},{"issue":"25","key":"704_CR21","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381(25):2416\u20132428","journal-title":"N Engl J Med"},{"issue":"6","key":"704_CR22","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","volume":"8","author":"Y Momozawa","year":"2022","unstructured":"Momozawa Y, Sasai R, Usui Y et al (2022) Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol 8(6):871\u2013878","journal-title":"JAMA Oncol"},{"issue":"13","key":"704_CR23","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/hmg\/10.13.1421","volume":"10","author":"M Sekine","year":"2001","unstructured":"Sekine M, Nagata H, Tsuji S et al (2001) Japanese familial ovarian cancer study group. Localization of 31 a novel susceptibility gene for familial ovarian cancer to chromosome 3p22-p25. Hum Mol Genet 10(13):1421\u20131429","journal-title":"Hum Mol Genet"},{"issue":"6349","key":"704_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409\u2013413","journal-title":"Science"},{"issue":"3","key":"704_CR25","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/cas.14798","volume":"112","author":"K Akagi","year":"2021","unstructured":"Akagi K, Oki E, Taniguchi H et al (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112(3):1105\u20131113","journal-title":"Cancer Sci"},{"issue":"8","key":"704_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamaoncol.2018.1482","volume":"4","author":"K Chang","year":"2018","unstructured":"Chang K, Taggart MW, Reyes-Uribe L et al (2018) Immune profiling of premalignant lesions in patients with Lynch syndrome. JAMA Oncol 4(8):1085\u20131092","journal-title":"JAMA Oncol"},{"issue":"8","key":"704_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11912-021-01085-z","volume":"23","author":"DM Pastor","year":"2021","unstructured":"Pastor DM, Schlom J (2021) Immunology of Lynch syndrome. Curr Oncol Rep 23(8):96","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"704_CR28","first-page":"257","volume":"17","author":"O Balat","year":"1996","unstructured":"Balat O, Kudelka AP, Ro JY et al (1996) Two synchronous primary tumors of the ovary and kidney: a case report. Eur J Gynaecol Oncol 17(4):257\u2013259","journal-title":"Eur J Gynaecol Oncol"},{"key":"704_CR29","unstructured":"Armstrong DK, Alvarez RD, Backes FJ et al. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) ovarian cancer continue including fallopian tube cancer and primary peritoneal cancer version 5.2022"},{"issue":"2","key":"704_CR30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ygyno.2004.04.020","volume":"94","author":"S Sundar","year":"2004","unstructured":"Sundar S, Symonds RP, Decatris MP et al (2004) Phase II trial of oxaliplatin and 5-fluorouracil\/leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecol Oncol 94(2):502\u2013508","journal-title":"Gynecol Oncol"},{"issue":"5","key":"704_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00404-008-0592-9","volume":"278","author":"DD Rosa","year":"2008","unstructured":"Rosa DD, Awada A, Mano MS et al (2008) Oxaliplatin\/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet 278(5):457\u2013462","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"704_CR32","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1186\/s12885-018-5180-1","volume":"18","author":"V Conteduca","year":"2018","unstructured":"Conteduca V, Gurioli G, Rossi L et al (2018) Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. BMC Cancer 18(1):1267","journal-title":"BMC Cancer"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-024-00704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-024-00704-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-024-00704-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:27:01Z","timestamp":1728505621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-024-00704-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["704"],"URL":"https:\/\/doi.org\/10.1007\/s13691-024-00704-3","relation":{},"ISSN":["2192-3183"],"issn-type":[{"type":"electronic","value":"2192-3183"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}